Pluripotent Stem Cell for Novel Drug Discovery

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 186

Special Issue Editor

E-Mail Website
Guest Editor
1. Department of Microbiology & Immunology, Georgetown University Medical Center, Washington, DC, USA
2. National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA
Interests: drug resistance mechanisms in human cancer; stem cells; drug discovery; regenerative medicine

Special Issue Information

Dear Colleagues,

The discovery of new drugs for diverse human diseases remains a significant challenge. A poor understanding of human pathology and inadequate representation of human diseases in animals impede the development of therapeutic drugs. Currently, the use of human pluripotent stem cell (hPSC)-based derivatives and disease modeling has revolutionized our drug discovery paradigms. Thus, hPSC-based models define a new pathway to enable the rapid development of effective small molecules or therapies for individual patients. In this Issue, we cover the mechanism of discovery of new drugs and highlight various hPSC platforms, which include 2D-monolayer culture, 3D tissues, and complex organoids, in the modeling of a broad range of diseases for preclinical drug development. We discuss the remaining challenges in the use of the above models and the opportunities in shaping ongoing pharmacological research.

Dr. Kevin G. Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Pluripotent stem cells
  • disease modeling
  • 2D-monolayer culture
  • 3D tissues
  • Organoids
  • drug discovery
  • drug development 

Published Papers

This special issue is now open for submission.
Back to TopTop